{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-006331","form_type":"8-K","ticker":"PMCB","cik":"0001157075","company_name":"PharmaCyte Biotech, Inc.","filed_at":"2023-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.247005+00:00","generated_at":"2026-06-10T22:33:49.166751+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PharmaCyte shareholders approve authorized share increase to 200M and financing-related issuance","bullets":["Shareholders approved issuance of shares ≥20% of outstanding related to May 2023 Securities Purchase Agreement (convertible preferred & warrants).","Increase in authorized common stock from 133,333,334 to 200,000,000 approved; amendment filed Sept 6, 2023.","Quorum: 11,422,363 shares (~68.01%). Proposal 1: 7.17M for, 0.4M against; Proposal 2: 9.98M for, 1.02M against."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-006331","json":"https://secwatch.observer/filing/0001683168-23-006331.json","markdown":"https://secwatch.observer/filing/0001683168-23-006331.md","text":"https://secwatch.observer/filing/0001683168-23-006331.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157075/000168316823006331/0001683168-23-006331-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157075/000168316823006331/pharmacyte_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T22:33:49.166751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"52b753434728a771f21f522fefcd40f4f4cf1eb4","claim":"PharmaCyte Biotech, Inc.: Increased authorized common stock from 133,333,334 to 200,000,000 shares (effective 2023-09-06).","evidence_excerpt":"the Company’s stockholders approved an amendment (the “Amendment”) to the Company’s Articles of Incorporation, as amended (the “Charter”), to increase the total number of authorized shares of the Company’s common stock from 133,333,334 to 200,000,000. On September 6, 2023, the Company filed the Amendment with the Secretary of State of the State of Nevada with immediate effect.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157075/000168316823006331/0001683168-23-006331-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-09-06"}],"fact_type":"governance_change"},{"claim_id":"11f07688902001bbe6911f8515c85cc4685d2a30","claim":"PharmaCyte Biotech, Inc. shareholders approved Approval of the Increase of Authorized Shares of Common Stock (Charter Amendment) at the 2023-08-31 meeting.","evidence_excerpt":"Proposal 2. Approval of the Increase of Authorized Shares of Common Stock. The approval of an amendment to the Charter to increase the total number of authorized shares of common stock from 133,333,334 to 200,000,000: For Against Abstain 9,982,019 1,019,080 421,264","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157075/000168316823006331/0001683168-23-006331-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-31"}],"fact_type":"shareholder_vote"},{"claim_id":"ddefcace3a3013821a08d584a8fb7516f1457640","claim":"PharmaCyte Biotech, Inc. shareholders approved Authorization of the Issuance of Shares (Nasdaq Listing Rule 5635(d)) at the 2023-08-31 meeting.","evidence_excerpt":"Proposal 1. Authorization of the Issuance of Shares. The authorization, for purposes of complying with Nasdaq Listing Rule 5635(d), of the issuance of shares of the Company’s common stock underlying shares of convertible preferred stock and warrants issued by the Company pursuant to the terms of that certain Securities Purchase Agreement, dated May 9, 2023, by and between the Company and the investors named therein, in an amount equal to or in excess of 20% of the Company’s common stock outstanding before the issuance of such convertible preferred stock and warrants (including any amortization payments made to the holders of convertible preferred stock in the form of issuance of shares of common stock and upon the operation of anti-dilution provisions contained in such convertible preferred stock and warrants): For Against Abstain Broker Non-Votes 7,170,025 400,161 432,796 3,419,381","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157075/000168316823006331/0001683168-23-006331-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-31"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}